基于voriconazole和esomeprazole之间药物相互作用的沃里可纳诱导的视觉异常:一个病例报告
概括
伏利康纳和埃索梅普拉之间的药物相互作用可能导致毒性伏利康纳水平,导致视觉异常. 治疗药物监测和剂量调整对于安全有效的沃里可纳治疗至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物新陈代谢 药物新陈代谢
背景情况:
- 沃里科纳是一种抗真菌药物,由CYP450酶代谢,主要是CYP2C19.
- 作为质子抑制剂的埃索梅普拉抑制CYP2C19,可能会影响voriconazole的代谢.
- 较高的伏利康纳水平可能导致严重的不良反应,包括视力障碍.
研究的目的:
- 报告一例沃里可纳引起的视觉异常.
- 为了研究voriconazole和esomeprazole之间药物相互作用的作用.
- 突出治疗药物监测和剂量调整的重要性.
主要方法:
- 一个81岁的男性患者的病例报告,患有视觉异常.
- 对沃里康纳血度的分析.
- 评估voriconazole和同时使用的esomeprazole之间的药物相互作用.
- 对涉及的CYP450酶途径的药理学评估.
主要成果:
- 当沃里科纳血度达到6.47 mg/L时,患者出现视觉异常.
- 与埃索梅普拉的同时使用通过CYP2C19抑制了沃里科纳的代谢,导致药物度升高.
- 将伏利康纳剂量减少50%可以解决视觉异常.
结论:
- 伏利康纳和埃索梅普拉之间的药物相互作用可能导致超治疗性伏利康纳水平和毒性.
- 建议在接受质子抑制剂,特别是埃索梅普拉的患者中对沃里可纳进行治疗药物监测.
- 基于监测的剂量调整对于获得最佳结果和最大限度地减少不良事件至关重要.
相关概念视频
Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
471
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
471
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
243
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
Antiepileptic Drugs: Potassium Channel Activators
212
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
212
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
199
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
199


